The Incidence of QT Prolongation and Torsades des Pointes in Patients Receiving Droperidol in an Urban Emergency Department
[Article]
Cole, Jon B.; Lee, Samantha C.; Martel, Marc L.; Smith, Stephen W.; Biros, Michelle H.; Miner, James R.
Introduction: Droperidol carries a boxed warning from the United States Food and Drug Administration for QT prolongation and torsades des pointes (TdP). After a six-year hiatus, droperidol again became widely available in the US in early 2019. With its return, clinicians must again make decisions regarding the boxed warning. Thus, the objective of this study was to report the incidence of QT prolongation or TdP in patients receiving droperidol in the ED.
2020
Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health
21/4
Cole, Jon B.; Lee, Samantha C.; Martel, Marc L.; Smith, Stephen W.; Biros, Michelle H.; Miner, James R.